Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
EBV-specific T cells (Ciusss de L'Est de l'Île de Montréal)
- Development stage
- Unknown
- Lead developer
- CIUSSS de l'Est-de-l'Île-de-Montréal
- Modality
- Cell Therapies
- Administration
- Intravenous
01
Overview
EBV-specific T cells (Ciusss de L'Est de l'Île de Montréal) is an investigational adoptive cell therapy consisting of donor-derived T lymphocytes that have been expanded *ex vivo* to specifically recognize and eliminate cells expressing Epstein-Barr Virus (EBV) antigens. Developed by the Ciusss de L'Est de l'Île de Montréal, this consolidative cellular immunotherapy is designed to treat EBV-associated malignancies, such as systemic EBV-positive lymphoma of childhood, and associated complications like hemophagocytic syndrome. The therapy is typically administered following allogeneic stem cell transplantation to provide immunological consolidation, leveraging the cytotoxic potential of the T cells to target residual EBV-infected B-cells while minimizing graft-versus-host disease.
- Other names
- EBV-specific T-cell linesEBV-CTLsEpstein-Barr Virus Specific T-Cell Lines
02
Targets
pMHC-I (Peptide–MHC class I complex)Epstein-Barr virus nuclear antigen 1 peptide-major histocompatibility complex
Beyond the preview
Go deeper on EBV-specific T cells (Ciusss de L'Est de l'Île de Montréal).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on EBV-specific T cells (Ciusss de L'Est de l'Île de Montréal).